文献速递泌尿生殖介入MR

MRI靶向单次大剂量近距离放疗治疗局限性前列腺癌:局灶放疗可行性研究(ProFocAL)

MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
PubMed 文献 · Eur Radiol · 2019-12-11

本研究建立并评估MRI引导下局灶大剂量率近距离放疗治疗前列腺癌的工作流程与安全性。9例低至中危、单发PI-RADS 4/5病灶患者接受单次20 Gy经臀徒手插管治疗,平均操作时间34分钟,VAS疼痛评分2–3分,6个月内无急性泌尿生殖或胃肠道毒性及感染,PSA显著下降,随访未见残留病灶。作者认为该方案可行且对个体患者安全。

要点

  • MRI引导下经臀徒手放置近距离放疗导管可准确将最高治疗剂量限制在肿瘤内。
  • 单次20 Gy局灶HDR近距离放疗无需全身麻醉或抗生素,体现微创特点。
  • 低至中危、单发PI-RADS 4/5病灶前列腺癌患者可能获益,治疗相关并发症较根治性治疗减少。

核心结论

  • MRI引导单次局灶HDR近距离放疗治疗局限性前列腺癌可行且对个体患者安全。
  • 导管可准确放置,最大治疗剂量分布可限制在肿瘤内。
  • 无需全身麻醉或抗生素,强调该操作的微创特点。
  • 低至中危前列腺癌患者尤其可能获益于延缓疾病进展,同时治疗相关并发症较根治性治疗减少。

研究设计与样本

  • 可行性研究,纳入组织学证实的局限性低至中危前列腺癌、单发PI-RADS 4/5病灶患者9例。
  • 使用3T-MRI,经臀徒手技术放置近距离放疗导管,行单次经皮间质HDR近距离放疗,大体肿瘤体积最小剂量20 Gy,同时保护危及器官。
  • 未给予抗生素治疗或全身性镇痛药。
  • 记录患者数据、操作时间、患者不适及并发症;计划每季度PSA监测、每半年随访影像、每年再活检。

关键影像表现/征象

  • 单发PI-RADS 4/5病灶为入组影像标准。
  • 随访影像(每半年)用于评估治疗区域,至今未见残留前列腺癌。

诊断标准与关键数值

  • 大体肿瘤体积最小剂量20 Gy,同时保护危及器官。
  • 采用VAS量表评估疼痛,干预相关疼痛评分为2至3分。
  • 短期随访至今无急性泌尿生殖或胃肠道毒性,无患者出现感染征象。
  • 所有患者PSA水平显著下降。

临床应用与阅片要点

  • 本研究表明MRI引导下经臀徒手放置导管可行,可将最大治疗剂量限制在肿瘤内。
  • 操作无需全身麻醉或抗生素,未给予全身性镇痛药,VAS疼痛评分为2至3分。
  • 作者认为低至中危前列腺癌患者尤其可能获益,治疗相关并发症较根治性治疗减少。
  • 原文未据此给出推荐。

局限性

  • 至今仅9例患者成功治疗并随访6个月。
  • 原文结论称该方案对个体患者可行且安全,未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of the study was to establish the setup and workflow for delivering focal MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer (PCA) and to assess patient comfort and safety aspects of MRI-guided single-fraction HDR.

METHODS: Patients with histologically proven focal low- to intermediate-risk PCA with a single PIRADS 4/5 lesion were treated with percutaneous interstitial HDR brachytherapy in a single fraction with a minimum dose for the gross tumor volume of 20 Gy while sparing the organ at risk (OAR). Using a 3T-MRI, brachytherapy catheters were placed transgluteal in freehand technique. No antibiotic therapy or general analgesics were administered. Patient data, procedure time, patient discomfort, and complications were recorded. Quarterly PSA controls, biannual follow-up imaging, and annual re-biopsy were planned.

RESULTS: So far, 9 patients were successfully treated and followed for 6 months. Mean intervention time was 34 min. Using the VAS scale, the pain reported for the intervention ranged from 2 to 3. Short-term follow-up showed no acute genitourinary or gastrointestinal toxicity so far. None of the patients displayed signs of infection. PSA levels in all patients decreased significantly. On follow up no residual PCA was detected treated region so far. PSA levels in all patients decreased significantly. On follow-up, no residual PCA was detected so far.

CONCLUSIONS: MR-guided single-fraction focal HDR brachytherapy for localized PCA is feasible as well as safe for the individual patient. Catheters can be placed accurately and maximum therapeutic dose distribution can be restricted to the tumor. Countersigning the minimally invasive character of the procedure, no general anesthesia or antibiosis is necessary.

KEY POINTS: • MR-guided focal HDR brachytherapy allows an accurate placement of catheters with maximum therapeutic dose distribution restricted to the tumor. • No major anesthesia or antibiosis is necessary emphasizing the minimal invasive character of the procedure. • Patients with low- and intermediate-risk prostate carcinoma in particular may benefit to halt disease progression whereas treatment-related morbidity is reduced compared with radical therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Fischbach F, Hass P, Schindele D, et al. MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL). Eur Radiol. 2019. PMID: 31828412. doi:10.1007/s00330-019-06505-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。